If one thing is for sure, it’s that Giorgio Vescera is not your average consulting and analytics expert. With years of experience in pharmacy and navigating the complexities of PBMs, he’s transitioned seamlessly into his role as Senior Director of Consulting and Analytics at AlignRx. But behind the numbers and corporate leadership is a small-town […]
Inside AlignRx: Employee Voices – Giorgio Vescera Read More »
Novo Nordisk, a global healthcare company, has recently announced the discontinuation of Levemir, a long-acting insulin, in the United States. This significant development, announced in November 2023, is set to reshape the landscape for many relying on this medication. Key Points of the Announcement: Impact Period: Expected to commence in January 2024 and span through
Levemir Discontinuation: What You Need to Know Read More »
See this article by AlignRx CEO Kevin Kobielski as it originally ran in Healthcare Business Today. Carve-outs can be a thorn in the side of health plans. But with a little creative thinking in key areas, insurers can solve the problems that cause employer groups to rely on carve-outs. For employers, the appeal of carve-outs
Why Carve-Outs Happen And How To Prevent Them Read More »
Below is an excerpt from an article by AlignRx chief pharmacy officer Beckie Fenrick and Goodroot area vice president of business development Brian Shonat that was recently published in BenefitsPRO. Following decades of patent litigation and maneuvering, the first biosimilar to Humira is now available with many more to follow this year. Humira is a
What Brokers and TPAs Need To Know About Humira Biosimilars Read More »
A new trend in insulin pricing? Here’s what you need to know. Insulin pricing has been a topic of concern and debate in recent years, as prices have skyrocketed, making it difficult for many patients with diabetes to afford the medication they need. However, the following recent announcements from major pharmaceutical manufacturers—who make up about
A Shake Up in the U.S. Insulin Market: Major Manufacturers Lower Insulin Costs Read More »
The industry report you’ve been waiting for. Today biosimilars seem to be the topic of conversation everywhere. Why? Humira. The launch of Humira biosimilars will be a test for industry stakeholders, as their entrance will reveal whether blockbuster drugs—that offer significant rebates—can be replaced to reduce the cost burden on patients and payers in the United States. Download our
Whitepaper: Breaking Down the Hottest Topic in Pharmacy—Humira Biosimilars Read More »
Brian Shonat, Goodroot’s area vice president of business development, recently joined Spencer Smith on the Self-Funded with Spencer podcast to talk AlignRx, PBM contracts, specialty drugs and more. Below are some of the highlights of what Brian had to say during the hour-long chat. Listen to the full episode on the Self-Funded with Spencer podcast.
AlignRx Highlighted on Self-Funded with Spencer Podcast Read More »
